British Business Bank life sciences backing reaches £1.13bn

Recent commitments include £135m to Advent Life Sciences and £100m to Apposite Healthcare Growth I

The British Business Bank has committed £1.13bn to UK life sciences, passing the £1bn milestone after announcing a new €58m (£48.5m) investment yesterday (18 November).

The new commitment to Sofinnova Crossover Fund II, a late-stage growth fund, follows an earlier investment in Sofinnova Capital XI.

Over the past decade, the bank has committed to specialist funds and made direct co-investments to address funding gaps in the UK sector.

The bank has committed £832m across 20 life sciences funds. Those funds have attracted £3.1bn in private capital – representing a 3.7x co-investment ratio.

Recent fund commitments include £135m across two Advent Life Sciences funds and £100m to Apposite Healthcare Growth I. It also committed $100m (£76.1m) to SV Health Investors’ SV8 Biotech Fund.

Since 2021, the bank has invested £302m directly into 28 growth-stage companies, half of which are academic spinouts.

Direct investments include £25m in Alchemab Therapeutics – its largest single life sciences investment – $20m (£15.2m) in Redx Pharma and £15m in Cambridge spinout T-Therapeutics.

Recent exits from the portfolio include Merck and Co’s acquisition of EyeBio for up to $3bn (£2.2bn) in 2024 and Terumo’s $1.5bn (£1.1bn) purchase of OrganOx in 2025. In 2026, academic spinout Myricx Bio agreed to an acquisition by Novartis worth up to $1.5bn (£1.1bn).

Leandros Kalisperas, chief investment officer of the British Business Bank, said: “The Bank is here to back British science. By supporting specialist fund managers and investing directly in high-growth companies, we are helping scientists convert research into commercial success. The true value of this milestone cannot be measured solely in pounds invested, but in the economic growth it creates and the patients’ lives it improves.

“From the discovery of penicillin to pioneering advances in DNA sequencing, British science has helped shape modern medicine and improve millions of lives around the world. Our scientific strength is a major investment opportunity, but realising that potential requires deep pools of capital through years of development.”

Chris Molloy, chief executive of BioIndustry Association, said: “The British Business Bank plays a welcome and vital role to turn world-class science into breakthrough medicines, skilled jobs and long-term value for taxpayers. The Bank is accelerating and closing the growth capital gap with deeper pools of late-stage capital to enable our most promising businesses to scale and stay in the UK."

Antoine Papiernik, chairman and managing partner of Sofinnova Partners, added: “The UK produces world-class science and its companies need specialist capital at the stages where it is hardest to find, something the British Business Bank has long understood. We are delighted to be building on our partnership with them and to be backing more of the UK’s best companies as they scale.”

The expansion of life sciences backing comes shortly after Chancellor John Healey allocated £5bn to the British Business Bank in the Budget to crowd in private capital. The Treasury’s financing strategy routes public borrowing through state lenders to co-invest alongside institutional managers in high-growth British businesses.

Previous Post
Two men in business attire look at a laptop screen while working at a long wooden table in an office.

65 Equity Partners hits $2bn in total commitments amid Koenigsegg stake

Next Post
Five people in business attire stand smiling on a balcony in front of a glass building.

Phoenix announces final close of Phoenix Insight Fund III at £570m